> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Enhertu Combo Delays Breast Cancer Progression
- URL: https://www.fdaweb.com/enhertu-combo-delays-breast-cancer-progression/
- Published: 2025-06-02T12:00:00.000Z
- Updated: 2026-09-14T15:13:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159282

A new combination therapy involving AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) and pertuzumab (Genentech’s Perjeta) has significantly extended progression-free survival for patients with HER2-positive metastatic breast cancer, according to results from the Phase 3 DESTINY-Breast09 trial presented 5/31 at the American Society of Clinical Oncology annual meeting. The study marks the first time in over a decade that a new treatment has demonstrated improved outcomes in the first-line setting for a broad population of patients with this aggressive form of breast cancer, AstraZeneca says.

In a prespecified interim analysis, the Enhertu-pertuzumab combination reduced the risk of disease progression or death by 44% compared to the current standard regimen of taxane, trastuzumab, and pertuzumab (THP), the company says. Median progression-free survival was 40.7 months for the Enhertu group versus 26.9 months for those receiving THP, it adds. The combination also produced a higher confirmed objective response rate (85.1% vs. 78.6%), with more complete responses (58 vs. 33) and a longer median duration of response — 39.2 months versus 26.4 months.

AstraZeneca says that while overall survival data remain immature, early signals indicate a potential benefit with the Enhertu regimen. The combination “nearly doubled the number of patients showing no signs of disease on imaging,” the company adds. Principal investigator **Sara Tolaney** called the results “potentially practice-changing,” adding, “These data show Enhertu and pertuzumab could become the new first-line standard for HER2-positive metastatic breast cancer.”